​

AstraZeneca (AZN) Stock Forecast, Price Target & Predictions

OverviewOwnershipChartTranscripts

AZN Stock Forecast

AstraZeneca (AZN) stock forecast, based on 41 Wall Street analysts, predicts a 12-month average price target of $97.00, with a high of $97.00 and a low of $97.00. This represents a 17.42% increase from the last price of $82.61.

$60 $68 $76 $84 $92 $100 High: $97 Avg: $97 Low: $97 Last Closed Price: $82.61

AZN Stock Rating

AstraZeneca stock's rating consensus is Buy, based on 41 Wall Street analysts. The breakdown includes 1 Strong Buy (2.44%), 19 Buy (46.34%), 15 Hold (36.59%), 6 Sell (14.63%), and 0 Strong Sell (0.00%).

Buy
Total 41 6 15 19 1 Strong Sell Sell Hold Buy Strong Buy

AZN Price Target Upside V Benchmarks

TypeNameUpside
StockAstraZeneca17.42%
SectorHealthcare Stocks 15.45%
IndustryDrug Manufacturers - General Stocks10.23%

Price Target Trends

1M3M12M
# Anlaysts--2
Avg Price Target--$92.50
Last Closing Price$82.61$82.61$82.61
Upside/Downside--11.97%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25262--10
Sep, 25272--11
Aug, 25272--11
Jul, 25462--12
Jun, 25561--12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 09, 2025Luisa HectorBerenberg Bank$97.00$70.8236.97%17.42%
Nov 13, 2024Etzer DaroutBMO Capital$88.00$81.198.39%6.52%
Sep 11, 2024Etzer DaroutBMO Capital$89.00$79.9411.33%7.74%
May 30, 2024John EadeArgus Research$85.00$76.8410.62%2.89%
May 28, 2024Etzer DaroutBMO Capital$82.00$76.746.85%-0.74%
Jul 12, 2023Andrew BerensLeerink Partners$79.00$64.8621.80%-4.37%
Jan 05, 2023BMO Capital$82.00$69.5017.99%-0.74%
Nov 11, 2022Leerink Partners$78.00$65.0919.83%-5.58%
May 04, 2022Leerink Partners$75.00$67.1711.66%-9.21%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 13, 2024BMO CapitalOutperformOutperformhold
Sep 13, 2024Deutsche BankSellHolddowngrade
Sep 12, 2024Deutsche BankHoldSelldowngrade
Sep 11, 2024BMO CapitalOutperformOutperformhold
Sep 11, 2024NordeaSelldowngrade
Aug 12, 2024Cowen & Co.BuyBuyhold
Jul 10, 2024BarclaysOverweightOverweighthold
Jul 02, 2024JefferiesHoldHoldhold
May 30, 2024Goldman SachsBuyinitialise
May 28, 2024BMO CapitalOutperformOutperformhold

Financial Forecast

EPS Forecast

$0 $1 $2 $3 $4 $5 $6 $7 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.22$0.04$1.06------
Avg Forecast$2.09$2.59$3.36$3.67$4.11$4.63$5.15$5.70$6.10
High Forecast$2.16$2.68$3.47$3.80$4.26$5.25$5.69$6.42$6.34
Low Forecast$2.01$2.49$3.16$3.58$4.05$4.40$4.57$5.25$5.85
Surprise %-41.63%-98.46%-68.45%------

Revenue Forecast

$25B $34B $43B $52B $61B $70B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$26.62B$37.42B$44.35B$45.81B-----
Avg Forecast$26.38B$36.41B$44.44B$45.81B$53.22B$56.79B$60.50B$64.28B$67.65B
High Forecast$27.02B$37.30B$45.54B$45.98B$53.59B$57.53B$60.61B$64.51B$69.72B
Low Forecast$25.56B$35.28B$42.41B$45.67B$52.69B$55.85B$60.39B$64.05B$65.51B
Surprise %0.91%2.76%-0.20%-0.00%-----

Net Income Forecast

$-5B $1B $7B $13B $19B $25B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.20B$112.00M$3.29B$5.96B-----
Avg Forecast$3.19B$-238.15M$-1.38B$5.96B$12.99B$15.08B$16.02B$18.22B$19.05B
High Forecast$3.83B$595.60M$-689.41M$8.94B$13.32B$16.40B$17.78B$20.04B$19.81B
Low Forecast$2.55B$-1.07B$-2.08B$2.97B$12.66B$13.76B$14.27B$16.40B$18.26B
Surprise %0.13%-147.03%-337.84%------

AZN Forecast FAQ

Is AstraZeneca stock a buy?

AstraZeneca stock has a consensus rating of Buy, based on 41 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 19 Buy, 15 Hold, 6 Sell, and 0 Strong Sell, reflecting a consensus that AstraZeneca is a favorable investment for most analysts.

What is AstraZeneca's price target?

AstraZeneca's price target, set by 41 Wall Street analysts, averages $97 over the next 12 months. The price target range spans from $97 at the low end to $97 at the high end, suggesting a potential 17.42% change from the previous closing price of $82.61.

How does AstraZeneca stock forecast compare to its benchmarks?

AstraZeneca's stock forecast shows a 17.42% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the drug manufacturers - general stocks industry (10.23%).

What is the breakdown of analyst ratings for AstraZeneca over the past three months?

  • October 2025: 20.00% Strong Buy, 60.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 18.18% Strong Buy, 63.64% Buy, 18.18% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 18.18% Strong Buy, 63.64% Buy, 18.18% Hold, 0% Sell, 0% Strong Sell.

What is AstraZeneca’s EPS forecast?

AstraZeneca's average annual EPS forecast for its fiscal year ending in December 2024 is $4.11, marking a 0% decrease from the reported $0 in 2023. Estimates for the following years are $4.63 in 2025, $5.15 in 2026, $5.7 in 2027, and $6.1 in 2028.

What is AstraZeneca’s revenue forecast?

AstraZeneca's average annual revenue forecast for its fiscal year ending in December 2024 is $53.22B, reflecting a 16.18% increase from the reported $45.81B in 2023. The forecast for 2025 is $56.79B, followed by $60.5B for 2026, $64.28B for 2027, and $67.65B for 2028.

What is AstraZeneca’s net income forecast?

AstraZeneca's net income forecast for the fiscal year ending in December 2024 stands at $12.99B, representing an 118.12% increase from the reported $5.96B in 2023. Projections indicate $15.08B in 2025, $16.02B in 2026, $18.22B in 2027, and $19.05B in 2028.